427 related articles for article (PubMed ID: 25332907)
1. Novel agents and new therapeutic approaches for treatment of multiple myeloma.
Ria R; Reale A; Vacca A
World J Methodol; 2014 Jun; 4(2):73-90. PubMed ID: 25332907
[TBL] [Abstract][Full Text] [Related]
2. Multiple Myeloma: New Insights and Therapeutic Approaches.
Anderson KC; Kyle RA; Dalton WS; Landowski T; Shain K; Jove R; Hazlehurst L; Berenson J
Hematology Am Soc Hematol Educ Program; 2000; ():147-165. PubMed ID: 11701540
[TBL] [Abstract][Full Text] [Related]
3. Current therapeutic strategy for multiple myeloma.
Suzuki K
Jpn J Clin Oncol; 2013 Feb; 43(2):116-24. PubMed ID: 23293370
[TBL] [Abstract][Full Text] [Related]
4. New treatments for myeloma.
Azaïs I; Brault R; Debiais F
Joint Bone Spine; 2010 Jan; 77(1):20-6. PubMed ID: 20031467
[TBL] [Abstract][Full Text] [Related]
5. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of novel therapies for the treatment of relapsed myeloma.
Richardson PG; Hideshima T; Mitsiades C; Anderson KC
J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
[TBL] [Abstract][Full Text] [Related]
7. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
9. Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies.
Larsen JT; Kumar S
Rare Cancers Ther; 2015; 3(1):47-68. PubMed ID: 27182478
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
11. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
12. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
13. Novel therapies in the treatment of multiple myeloma.
Laubach JP; Mitsiades CS; Mahindra A; Schlossman RL; Hideshima T; Chauhan D; Carreau NA; Ghobrial IM; Raje N; Munshi NC; Anderson KC; Richardson PG
J Natl Compr Canc Netw; 2009 Oct; 7(9):947-60. PubMed ID: 19878638
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.
Donato F; Gay F; Bringhen S; Troia R; Palumbo A
Expert Opin Biol Ther; 2014 Aug; 14(8):1127-44. PubMed ID: 24749510
[TBL] [Abstract][Full Text] [Related]
15. Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice.
Lee HS; Min CK
Korean J Intern Med; 2016 Sep; 31(5):809-19. PubMed ID: 27604793
[TBL] [Abstract][Full Text] [Related]
16. New approaches to management of multiple myeloma.
Genadieva-Stavric S; Cavallo F; Palumbo A
Curr Treat Options Oncol; 2014 Jun; 15(2):157-70. PubMed ID: 24578203
[TBL] [Abstract][Full Text] [Related]
17. New strategies in the treatment of multiple myeloma.
Munshi NC; Anderson KC
Clin Cancer Res; 2013 Jul; 19(13):3337-44. PubMed ID: 23515406
[TBL] [Abstract][Full Text] [Related]
18. Novel investigational drugs active as single agents in multiple myeloma.
D'Agostino M; Salvini M; Palumbo A; Larocca A; Gay F
Expert Opin Investig Drugs; 2017 Jun; 26(6):699-711. PubMed ID: 28448171
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor therapy in multiple myeloma.
Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
Mian M; Tinelli M; DE March E; Turri G; Meneghini V; Pescosta N; Berno T; Marabese A; Mondello P; Patriarca F; Pizzolo G; Semenzato G; Cortelazzo S; Zambello R
Anticancer Res; 2016 Mar; 36(3):1059-65. PubMed ID: 26976998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]